PubRank

Hiroshi Yasui

Author PubWeight™ 51.74‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005 3.41
2 Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006 3.04
3 The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009 2.25
4 Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005 1.99
5 JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 2007 1.89
6 Loss-of-function mutations of CHST14 in a new type of Ehlers-Danlos syndrome. Hum Mutat 2010 1.83
7 Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005 1.79
8 Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A 2007 1.77
9 PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010 1.75
10 MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006 1.75
11 Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006 1.72
12 SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2008 1.47
13 The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A 2006 1.46
14 Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007 1.41
15 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007 1.36
16 Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 2005 1.23
17 MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007 1.21
18 Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res 2007 1.13
19 Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004 1.05
20 Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res 2009 1.03
21 Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene 2005 0.97
22 A new Ehlers-Danlos syndrome with craniofacial characteristics, multiple congenital contractures, progressive joint and skin laxity, and multisystem fragility-related manifestations. Am J Med Genet A 2010 0.97
23 Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005 0.95
24 Granulocyte colony-stimulating factor-producing esophageal squamous cell carcinoma following chemoradiotherapy and bone marrow transplantation for acute lymphoblastic leukemia. Esophagus 2013 0.93
25 Gastropleural fistula derived from malignant lymphoma. J Gastroenterol 2002 0.92
26 Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene 2005 0.91
27 Retracted Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol 2008 0.85
28 Epstein-Barr virus-infected cells in IgG4-related lymphadenopathy with comparison with extranodal IgG4-related disease. Am J Surg Pathol 2014 0.85
29 A case of adult T cell leukemia/lymphoma presenting as severe tracheal stenosis. Intern Med 2011 0.84
30 Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1). Jpn J Clin Oncol 2009 0.84
31 In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br J Haematol 2006 0.82
32 Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy. J Infect Chemother 2012 0.81
33 Overexpression of BAD preferentially augments anoikis. Int J Cancer 2003 0.80
34 In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody. Oncol Rep 2011 0.80
35 Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo. PLoS One 2011 0.80
36 Synchronous mucosa-associated lymphoid tissue lymphoma and gastrointestinal stromal tumor of the stomach presenting with gastric bleeding. Am Surg 2008 0.78
37 Accumulation of 99mTc-PMT in renal metastasis of hepatocellular carcinoma. Ann Nucl Med 2003 0.78
38 [Sustained complete molecular remission after cessation of imatinib mesylate treatment in a patient with relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation]. Rinsho Ketsueki 2012 0.77
39 Combination therapy of DDAVP and conjugated estrogens for a recurrent large subcutaneous hematoma in Ehlers-Danlos syndrome. Am J Hematol 2003 0.76
40 A case of pediatric gastrointestinal stromal tumor of the stomach. Pediatr Int 2005 0.75
41 Hepatitis B virus-associated aplastic anemia followed by myelodysplastic syndrome. Am J Med 2002 0.75
42 Submucosal hematoma is a highly suggestive finding for amyloid light-chain amyloidosis: Two case reports. World J Gastrointest Endosc 2012 0.75
43 Pulmonary Tumor Thrombotic Microangiopathy Caused by a Parotid Tumor: Early Antemortem Diagnosis and Long-term Survival. Intern Med 2017 0.75
44 [Pancreatic cancer in a patient with congenital agenesis of the dorsal pancreas]. Nihon Shokakibyo Gakkai Zasshi 2013 0.75
45 [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation]. Rinsho Ketsueki 2011 0.75
46 [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma]. Rinsho Ketsueki 2005 0.75
47 A case of neurosarcoidosis with recurrent episodes of neurological dysfunction and diffuse cortical lesions on magnetic resonance imaging. Rinsho Shinkeigaku 2009 0.75
48 [Usefulness of serum free light-chain assay for evaluation of therapeutic efficacy in non-secretory multiple myeloma]. Rinsho Ketsueki 2013 0.75
49 Mucormycosis as an etiology of cerebral hemorrhage in patients with chronic neutrophilic leukemia. Am J Med 2003 0.75
50 [A case of pathological complete response after chemotherapy for liver metastasis with subcapsular hemorrhage from gastric cancer:]. Gan To Kagaku Ryoho 2012 0.75
51 [Long-term survival after autologous peripheral blood stem cell transplantation in a patient with primary AL amyloidosis complicating congestive heart failure]. Rinsho Ketsueki 2007 0.75